Excimer laser coronary atherectomy (ELCA) has been used for the treatment of complex percutaneous coronary intervention (PCI) such as in-stent restenosis (ISR). However, little information was provided about the clinical outcomes after treatment with ELCA for ISR of drug-eluting stents (DES). This study aimed to investigate the long-term clinical outcomes after PCI with ELCA for ISR of DES. A total of 81 consecutive patients with 87 lesions who underwent PCI for ISR of DES were included. Patients were classified into a PCI with ELCA group (23 patients with 24 lesions) and a PCI without ELCA group (58 patients with 63 lesions). The major adverse cardiac events (MACE) were evaluated. The mean duration of clinical follow-up was 29.8 ± 11.6 months. The incidences of diffuse restenosis and AHA/ACC type B2 or C lesion in the PCI with ELCA group were higher than in the PCI without ELCA group. Quantitative coronary angiography showed the acute luminal gain in the PCI with ELCA group was greater than in the PCI without ELCA group (1.64 ± 0.48 mm versus 1.26 ± 0.42 mm, P < 0.001). There were no significant differences in all-cause death, myocardial infarction, or target lesion revascularization between the 2 groups. Multivariate analysis due to a Cox proportionalhazards model showed that multivessel disease was an independent predictor of MACE (hazard ratio 3.05, 95% confidence interval 1.22 to 7.61, P = 0.02). ELCA was effective as an atherectomy device for lumen enlargement and optimal lesion preparation. Even though ELCA was used for ISR of DES in significantly more complex lesions, the long-term clinical outcomes were favorable and similar.
D rug-eluting stents (DES) dramatically reduced the rate of in-stent restenosis (ISR) compared to bare-metal stents in a randomized trial. 1) Moreover, the clinical outcomes have further improved with the advent of second-generation DES. 2) However, with the increasing use of DES and the frequent implantation of a DES into complex lesions, ISR has become a challenging problem in percutaneous coronary intervention (PCI). 3) 
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Excimer laser coronary atherectomy (ELCA) has been effective for PCI of complex lesions, including stent restenosis, calcified lesions, chronic total occlusion, and ostial and long lesions. 4) ELCA has been useful to facilitate stent expansion in balloon-resistant lesions. 5) However, there is little information about the clinical outcomes after treatment with ELCA for ISR. Thus, the present study evaluated the long-term clinical outcomes after PCI with ELCA for ISR of DES.
Methods
Patients: Between January 2012 and March 2015, a total of 913 consecutive patients with 1024 lesions underwent PCI at the Department of Invasive Cardiology, Englewood Hospital and Medical Center. Of these, 81 consecutive patients (8.9%) with 87 lesions (8.5%) who underwent PCI for ISR of DES were included in this study. According to the use of ELCA, patients were classified into a PCI with ELCA group (23 patients with 24 lesions) and a PCI without ELCA group (58 patients with 63 lesions). This study was approved by the local council on human research. Procedure: PCI was performed using standard techniques after written informed consent was obtained. 6) After stent implantation, angiographic optimization was performed using high-pressure balloon dilatation to achieve an acceptable angiographic result with < 20% residual stenosis by visual estimate. The decision to perform atheroablation with ELCA was made by the operator. In lesions treated with an excimer laser system (CVX-300, Spectranetics, Colorado Springs, CO), a 0.9 mm laser catheter was used. The energy was delivered at a fluence of 60 to 80 mJ/ mm 2 . The saline infusion technique was used in all cases. 7) The use of intravascular ultrasound (IVUS) and a cutting balloon was selected at the operator's discretion. Drugeluting balloons and other atherectomy devices such as rotational atherectomy were not used in the same period as this study, while the use of cutting balloons and/or noncompliant balloons was permitted. Restenting for ISR lesions was performed only when it was required to optimize final angiographic results or to cover extensive dissections after ELCA and balloon angioplasty. Angiographic analysis: Quantitative coronary angiography was performed using a computer-assisted automated edge-detection system (MDQM-QCA, Medcon Limited, Tel Aviv, Israel) with a contrast-filled catheter as the calibration standard. Reference vessel diameter, minimal lumen diameter (MLD), lesion length, and percent diameter stenosis were analyzed. MLD was obtained from the single "worst" view. The angiographic patterns of in-stent restenosis proposed by Mehran, et al were used. 8) Lesions were characterized according to the modified American Heart Association/American College of Cardiology classification. 9) The subanalysis of quantitative coronary angiography was performed to eliminate the differences in the MLD before the procedure. Quantitative angiographic results of the without ELCA group in smaller and similar MLD before the procedure were compared to those of the with ELCA group. An MLD of 0.9 mm, the same size as the laser catheter, was defined as the cutoff level. Lesions (MLD before the procedure < 0.9 mm) were classified into the with ELCA group (19 lesions) or the without ELCA group (29 lesions) . Clinical follow-up: Baseline demographic and clinical data along with in-hospital outcomes were obtained by review of the medical records and procedural reports. Clinical follow-up data were obtained from outpatient record reviews. Stent thrombosis was defined as the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion. 10) The occurrence of any major adverse cardiac event (MACE) including death from any cause, myocardial infarction, and target lesion revascularization (TLR) was recorded. Statistical analysis: Statistical analysis was performed with SAS version 9.4 (SAS Institute, Cary, NC, USA). Continuous variables are expressed as the mean ± SD and categorical variables as the frequency (%). Continuous variables were compared using Student's t-test or analysis of variance. Categorical variables were compared with chi-square statistics or Fisher's exact test. The Kaplan-Meier method was used for the estimation of event-free survival during follow-up and differences between the curves were compared using log-rank analysis. A P value < 0.05 was considered significant. Univariate analysis of factors affecting event-free survival was performed using the factors in Table I , II, III. Multivariate analysis was performed using the Cox proportional-hazards model. Variables with a P value < 0.10 in univariate analysis were included in the multivariate model.
Results
The baseline clinical characteristics of the patients are presented in Table I . Diabetes mellitus and prior bypass surgery were higher in the PCI with ELCA group than in the PCI without ELCA group. There was no significant difference in left ventricular ejection fraction between the 2 groups. Table II shows the angiographic and procedural characteristics. The incidence of a saphenous vein graft was higher in the with ELCA group than in the without ELCA group (20.8% versus 1.6%, P = 0.002). The incidences of diffuse restenosis (83.3% versus 54.0%, P = 0.007) and an AHA/ACC type B2 or C lesion in the PCI with ELCA group were higher than in the PCI without ELCA group. There was no significant difference in the use of a cutting balloon and additional stent implantation between the 2 groups. Stent diameter, maximum balloon diameter, and balloon inflation in the with ELCA Ichimoto, ET AL group were higher than in the without ELCA group. The results of quantitative coronary angiographic analysis are shown in Table III . Before the procedure, the MLD was significantly lower and the diameter stenosis rate was higher in the with ELCA group than in the without ELCA group. After the procedure, there was no significant difference in reference diameter, MLD, or percent diameter stenosis between the 2 groups. Figure 1 shows acute luminal gain after the procedure. Acute luminal gain was greater in the PCI with ELCA group than in the PCI without ELCA group (1.64 ± 0.48 mm versus 1.26 ± 0.42 mm, P < 0.001). The quantitative angiographic results in the subgroup of 48 lesions with smaller and similar MLD before the procedure (MLD before the procedure < 0.9 mm) are shown in Table IV . Before the procedure, there was no significant difference in the MLD and percent diameter stenosis between the 2 groups. However, the acute luminal gain was greater in the PCI with ELCA group than in the PCI without ELCA group.
Mean duration of clinical follow-up was 29.8 ± 11.6 months. There were no significant differences in death, myocardial infarction, TLR, or stent thrombosis between the 2 groups (Table V) .
Kaplan-Meier curves showed that there was no statistically significant difference in event-free survival between the PCI with and without ELCA groups (Figure 2 ). VI presents the results of multivariate analysis. Multivessel disease was an independent predictor of cardiovascular events during follow-up.
Discussion
The present study showed greater acute luminal gain after PCI with ELCA for ISR of DES. Furthermore, there was slightly less TLR in patients with ELCA for ISR compared to those without ELCA. Even though ELCA for ISR was used in the more complex lesions, there was no statistically significant difference in cardiovascular events between patients with and without ELCA.
The influence of DES has increased in the invasive treatment of patients with coronary artery disease. DES substantially reduced ISR compared to bare-metal stents in a randomized trial. 1) However, ISR remains an important clinical problem. 11) One of the important risk factors for ISR is stent underexpansion. 12) Implantation of another stent within the underexpanded stent may lead to recurrent restenosis or stent thrombosis. 13) It is well established that the underlying substrate is different in patients with ISR of DES and bare-metal stents. 14, 15) Pathological findings of ISR suggest that neoatherosclerosis is significantly more prevalent in patients with DES than in those with a baremetal stent. 16 with ISR. 17) The additional stent implantation for ISR lesions of DES performed in the present study was similar between the with and without ELCA groups (41.7% versus 46.0%, P = 0.71). In the treatment of ISR lesions, DES implantation was markedly more effective with a lower incidence of TLR compared to balloon angioplasty using a drugeluting balloon. 17) On the other hand, DES implantation for restenosis of DES was associated with a higher risk of myocardial infarction or stent thrombosis compared with balloon angioplasty. 18) Stent implantation for recurrent restenosis lesions was recommended in only residual stenosis lesions after balloon angioplasty because a larger acute gain and postprocedural lumen area were associated with a lower restenosis rate regardless of the reference vessel size. 19) For these reasons, restenting for ISR lesions was performed only when it was required to optimize final angiographic results or to cover extensive dissections after ELCA and balloon angioplasty in this study.
In the present study, the maximum balloon inflation pressure in the with ELCA group was higher than in the without ELCA group. A previous study demonstrated that the mechanisms of ISR after DES implantation were significant intimal hyperplasia and stent underexpansion by IVUS analysis. 13) The lesion characteristics in the PCI with ELCA group were significantly more complex and severe than in the PCI without ELCA group. These might be strongly associated with stent underexpansion. For this reason, balloon dilatation with higher pressure for an underexpanded stent might be necessary as well as neointimal tissue ablation during ELCA. This was one of the possible reasons that maximum balloon inflation pressure was higher in the with ELCA group. However, it was unclear because the use of IVUS was limited in this study.
Intravascular imaging has been considered a useful adjunctive tool when treating ISR lesions and can be used to identify the mechanism of restenosis and for the evaluation of plaque morphology. 20, 21) Mehran, et al showed that the mechanism of lumen enlargement during PCI of ISR was a combination of additional stent expansion and tissue extrusion outside the stent segment by IVUS. 22) Optical coherence tomography (OCT) findings after ELCA showed reducing in-stent neointimal tissue by ablation and then creating tissue surface to facilitate balloon expansion. 23) Furthermore, OCT has shown that ELCA facilitated fracturing of diffuse calcium behind an underexpanded stent. 24) For these reasons, OCT findings offer an insight into both the mechanism of ELCA and its potential use to aid in decision-making concerning PCI.
The present study evaluated the long-term clinical outcome after treatment for ISR of DES. However, routine angiographic follow-up was not performed. The patients who underwent PCI with ELCA included more complex lesions than those without ELCA. Intravascular imaging was used only partly. There was no significant difference in the use of IVUS between the PCI with and without ELCA groups. ELCA is based on ultraviolet energy and is capable of disintegrating an atheroma, without burning or grossly fragmenting the atheroma. The underlying principle is that the excimer laser uses energy to disrupt and disintegrate the molecular bonds within the atherosclerotic plaque in a highly controlled manner, thereby acting through ablation rather than burning. 25) Intracoronary saline irrigation is performed to flush blood and contrast in order to decrease vapor bubble formation. 26) Saline infusion has significantly increased procedural safety. 7) ELCA has been shown to be both safe and effective for plaque modification in severely calcified plaques and chronic total occlusions, in which balloons have failed to cross or expand the lesions. 27) ELCA has been previously reported to facilitate stent expansion in balloon-resistant lesions. 28) The Excimer Laser Lesion Modification to Expand Non-dilatable sTents (ELLEMENT) registry confirmed the efficacy and reproducibility of ELCA with contrast injection to modify the underlying plaque and improve stent expansion in undilatable lesions. 29) The bioresorbable vascular scaffold (BVS) needs optimal lesion preparation in order to maximize the mechanical properties of the scaffold. The acute recoil of the BVS was significantly greater than that of the metallic everolimuseluting stent. 30) Therefore, ELCA may be useful for optimal lesion preparation before treatment with the BVS.
A previous study demonstrated the safety of using ELCA for ISR and volumetric IVUS analysis showed that tissue ablation during ELCA contributed 29%, tissue extrusion during adjunct PCI contributed 31%, and additional stent expansion during adjunct PCI contributed 40% to the overall lumen gain with treatment of ISR. 31) The mechanism of lumen enlargement after ELCA of ISR was neointimal tissue ablation. On the other hand, Mintz, et al indicated that the mechanism of lumen enlargement after ELCA of nonstented lesions was a combination of tissue ablation and vessel expansion. 32) Köster, et al reported that ELCA for ISR was associated with a high incidence of recurrent restenosis after 6 months. 33) The Laser Angioplasty for Restenotic Stents (LARS) multicenter registry compared balloon angioplasty to ELCA in patients with ISR. 34) The study findings showed ELCA-treated patients had similar rates of major cardiac events and target lesion re-vascularization at 1 year. 35) The 0.9 mm laser catheter used in the present study is a smaller catheter capable of delivering higher energy density (up to 80 mJ/mm 2 ) and higher pulse repetition rates (up to 80 Hz) than previous large laser catheters. This catheter features a high optical fiber packing density to maximize the cutting area at the distal tip. This smaller catheter was safe and effective in patients presenting with complex calcified and balloon-resistant lesions. 36) The characteristics of this improved laser catheter might be related to the angiographic and procedural results of this study.
The mean duration of clinical follow-up in this study was 29.8 ± 11.6 months. Despite the greater acute luminal gain after PCI with ELCA for ISR of DES, there were no significant differences in death, myocardial infarction, TLR, or stent thrombosis. ELCA has various benefits to modify in-stent intimal hyperplasia and improve the optimal expansion of an undilatable and underexpanded stent although this study could not demonstrate any dramatic improvement of long-term cardiovascular events. Moreover, ELCA is safe and useful for complex lesions such as ISR, but treatment using ELCA is more expensive than other strategies using only a cutting balloon and therefore the number of institutions capable of performing ELCA treatment is limited. For these reasons, it may be difficult to assess the superiority and inferiority of ELCA based on only the results of the present study.
In the present study, multivessel disease was an independent predictor of cardiovascular events during followup. Orlic, et al reported that multivessel sirolimus-eluting stent implantation for the treatment of multivessel coronary artery disease increased the need for revascularization. 37) On the other hand, a previous study showed that the only independent predictors of subsequent target vessel revascularization were aorto-ostial lesion location and an acute procedural decrease in in-stent intimal hyperplasia cross-sectional areas for the treatment of ISR with ELCA. 31) Study limitations: There are several limitations in the present study. The sample size was small and it was not a randomized trial. There might be selection bias between with and without ELCA. Furthermore, the use of a drugeluting balloon and rotational atherectomy were not included. Volumetric IVUS analysis was not included because the use of IVUS was limited in the present study. This was a retrospective study with a small number of patients, and this might be related to the lack of significant differences in death, myocardial infarction, and TLR between the 2 groups. ELCA is effective at facilitating balloon or stent expansion by ablating in-stent intimal hyperplasia and improving optimal lesion preparation in undilatable and underexpanded stents. Because of the potential importance of ELCA for the treatment of ISR, randomized trials in a larger number of patients are justified.
Conclusions
ELCA was introduced in severe ISR lesions of DES and was found to be effective as an atherectomy device for lumen enlargement and optimal lesion preparation. Even though ELCA for ISR of DES was used in signifi-cantly more complex lesions, the long-term clinical outcomes were favorable and similar.
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